We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Federal Judge Tells FDA it Must Make Public 55,000 Pages a Month of Pfizer Vaccine Data

Federal Judge Tells FDA it Must Make Public 55,000 Pages a Month of Pfizer Vaccine Data

January 10, 2022

A federal judge in Texas has ruled that the FDA must by the end of this month make public 12,000 pages of the data it used to make decisions about approvals for Pfizer/BioNTech’s COVID-19 vaccine — and then release 55,000 pages every 30 days after that until all 450,000 requested pages are public.

The request for FDA’s Pfizer/BioNTech data flows from an August 2021 Freedom of Information Act (FOIA) request from the nonprofit group Public Health and Medical Professionals for Transparency (PHMPT), filed just after the FDA granted full approval to the vaccine for people 16 and older.

In response to the FOIA request, the FDA had previously said that it takes approximately eight minutes per page to process records for a FOIA request, and that it could only review and release 500 pages a month, which is 6,000 pages a year.

At that rate, it would take 75 years to release all the data.

In his Jan. 6 ruling, U.S. District Judge Mark Pittman said the court “concludes that this FOIA request is of paramount public importance.”

Pittman, from the U.S. District Court for the Northern District of Texas Fort Worth Division, is a 2019 appointee of President Trump.

PHMPT is made up of about 200 doctors, scientists, professors, public health professionals and journalists, including some who have publicly questioned the usefulness of lockdowns, mask mandates and the COVID-19 vaccine. The group focuses entirely on data relied upon by the FDA to license COVID-19 vaccines, the organization said on its website.

The group has said it will publish all the information the FDA makes public about the Pfizer/BioNTech vaccine.

If the agency can keep up with the 55,000-pages-a-month requirement, all the data should be in the public domain by summer’s end.

Neither the FDA nor PHMPT responded to requests for comment.

Reach the judge’s order here: www.fdanews.com/01-07-22-PittmanFOIAOrder.pdf. — Suz Redfearn

COVID-19

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FemDx Medsystems Falloposcope Cleared

  • Cyclerion’s Mitochondrial Diseases Candidate Gets Orphan Drug Nod

  • Surmodics Gets FDA’s Feedback on Rejected PMA

  • EU Approves Amicus Therapeutics Pombiliti for Late-Onset Pompe Disease

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing